Xtant director granted 215K deferred stock units

Xtant Medical Holdings, Inc. (XTNT) reported that director John K. Bakewell received a grant of 215,517 deferred stock units (DSUs) of common stock at no cash cost, classified as a grant/award acquisition.

Rhea-AI Filing Summary

Xtant Medical Holdings, Inc. (XTNT) reported that director John K. Bakewell received a grant of 215,517 deferred stock units (DSUs) of common stock at no cash cost, classified as a grant/award acquisition. The DSUs vest on August 15, 2027, conditioned on his continued service as a director, with settlement of the vested shares deferred to a later date under the DSU award agreement. After this award, he holds 1,129,633 shares of common stock directly, including 681,087 shares issuable upon settlement of previously granted DSUs.

Insider Trade Summary

Grant/Award: 215,517 shares

Grant/Award 1 txn

Insider BAKEWELL JOHN K

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	215,517	$0.00	$0.00

Holdings After Transaction: Common Stock — 1,129,633 shares (Direct)

Footnotes (2)

1. F1. These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on August 15, 2027, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.
2. F2. Includes 681,087 shares issuable upon settlement of DSUs granted under the Xtant Medial Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting date.

Key Figures

DSUs granted: 215,517 shares Transaction price per share: $0.0000 Vesting date: August 15, 2027 +2 more

5 metrics

DSUs granted 215,517 shares Deferred stock unit award of common stock to director on August 15, 2026

Transaction price per share $0.0000 Reported price for the DSU grant classified as a grant/award acquisition

Vesting date August 15, 2027 DSU award vests if the reporting person remains a director through this date

Total shares after transaction 1,129,633 shares Direct holdings of Xtant Medical common stock following the DSU grant

Shares issuable from DSUs 681,087 shares Included within total holdings, issuable upon settlement of prior DSU grants

Key Terms

deferred stock unit (DSU), Amended and Restated 2023 Equity Incentive Plan, vest, settlement, +1 more

5 terms

deferred stock unit (DSU) financial

"These shares are subject to a deferred stock unit (DSU) award granted"

Amended and Restated 2023 Equity Incentive Plan financial

"granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan"

vest financial

"and will vest on August 15, 2027, conditioned upon the Reporting Person"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

settlement financial

"The settlement of the vested shares underlying the DSU award has been deferred"

Settlement is the process of completing a financial transaction, like buying or selling a stock, by transferring money and ownership between parties. It ensures that both the buyer gets the asset and the seller gets paid, making the deal official. Without settlement, the transaction wouldn't be finalized or legally recognized.

contingent right financial

"Each DSU represents a contingent right to receive one share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did XTNT director John K. Bakewell receive in this Form 4 filing?

John K. Bakewell received a grant of 215,517 deferred stock units (DSUs) of Xtant Medical common stock. These DSUs are a form of equity compensation that convert into one share each upon settlement after meeting vesting and service conditions.

When do John K. Bakewell’s new XTNT deferred stock units vest?

The 215,517 new DSUs for XTNT will vest on August 15, 2027, provided Bakewell remains a director through that date. The filing states settlement of the vested shares will occur later according to the DSU award agreement’s terms.

How many XTNT shares does John K. Bakewell hold after this transaction?

After this reported transaction, John K. Bakewell holds 1,129,633 shares of Xtant Medical common stock directly. This figure includes 681,087 shares that are issuable upon settlement of previously granted DSUs, subject to their respective vesting conditions.

Was there any cash price paid for the XTNT shares in this Form 4 grant?

No cash price was paid for this grant; the transaction price per share is reported as $0.0000. The acquisition is categorized as a grant, award, or other acquisition of DSUs under Xtant Medical’s equity incentive plan.

Under which plan were the new XTNT deferred stock units granted to John K. Bakewell?

The DSUs were granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan. The filing notes that each DSU is a contingent right to receive one share of Xtant Medical common stock upon settlement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 06:28 PM Accepted by SEC EDGAR 08/18/2026 - 06:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BAKEWELL JOHN K

(Last) (First) (Middle)

C/O XTANT MEDICAL HOLDINGS, INC.

664 CRUISER LANE

(Street)

BELGRADE MONTANA 59714

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xtant Medical Holdings, Inc. [ XTNT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2026		A		215,517(1)	A	$0	1,129,633(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on August 15, 2027, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

2. Includes 681,087 shares issuable upon settlement of DSUs granted under the Xtant Medial Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting date.

	/s/ Amy Culbert, attorney-in-fact	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)